Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction.

@article{Lebovitz2002EvaluationOL,
  title={Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction.},
  author={Harold E. Lebovitz and Margaret M Kreider and Martin I. Freed},
  journal={Diabetes care},
  year={2002},
  volume={25 5},
  pages={815-21}
}
OBJECTIVE Troglitazone treatment has been associated with idiosyncratic hepatic reaction leading to hepatic failure and death in some patients. This raises questions regarding whether all thiazolidinediones or peroxisomal proliferator-activated receptor-gamma (PPAR-gamma) agonists are hepatotoxic and whether data from clinical trials are adequate to detect a signal of potentially serious drug-related hepatotoxicity. The purpose of this study was to assess whether the idiosyncratic liver… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 52 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 43 references

Absorption, disposition, and metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizer, in humans.

Drug metabolism and disposition: the biological fate of chemicals • 2000
View 1 Excerpt

The synthesis of BRL 49653 : a novel and potent antihyperglycaemic agent

Cantello BCC, MA Cawthorne, +3 authors PL Thurlby
Biorg Med Chem Lett • 2000

Rosiglitazone, a PPAR agonist, does not alter the pharmacokinetics of oral contraceptives (OC) (Abstract)

AML Inglis, AK Miller, +4 authors MI Freed
Diabetes 48 (Suppl. 1):A103, • 1999
View 1 Excerpt

Similar Papers

Loading similar papers…